Article Text

Download PDFPDF
Effects of a novel tyrosine kinase inhibitor in rheumatoid arthritis synovial fibroblasts
  1. L C Huber1,
  2. P Künzler1,
  3. S H Boyce2,
  4. B A Michel1,
  5. R E Gay1,
  6. B S Ink2,
  7. S Gay1
  1. 1
    Center of Experimental Rheumatology, University Hospital Zurich, and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland
  2. 2
    GlaxoSmithKline, Medicines Research Centre, Stevenage, UK
  1. L C Huber, Center of Experimental Rheumatology, University Hospital Zurich, Gloriastrasse 25, CH-8091 Zurich, Switzerland; Lars.Huber{at}


Objective: Biologicals have revolutionised the treatment of rheumatoid arthritis (RA). However, progressive joint destruction can still be observed in many patients and the search for novel molecular therapies targeting specific signalling pathways is ongoing. In the present study, we investigated the effects of GW282974, a novel compound directed against tyrosine kinase activity with respect to the potential suppression of inflammation and destruction.

Methods: Synovial tissue specimens were obtained from RA patients undergoing surgical joint replacement. Rheumatoid arthritis synovial fibroblasts (RASFs) were stimulated with cytokines and GW282974 was added in different concentrations. Gene expression was checked by TaqMan PCR, using 18S as housekeeping gene. Protein analysis was quantified by ELISA. Cell growth and proliferation was measured using the “ViaLight” proliferation assay.

Results: EGF had no effect on the gene expression profile of RASFs when used as single stimulatory agent. In combination with pro-inflammatory mediators however, EGF showed a synergistic effect. The expression of matrix metalloproteinases, inflammatory cytokines and cyclooxygenase-2 on mRNA levels was strongly increased, whereas the addition of GW282974 abrogated these effects in a dose-dependent manner. These data could be confirmed on protein/lipid levels analysing the supernatants of RASFs by ELISA. Similarly, cell growth and proliferation of RASFs were inhibited by GW282974 in a dose- and time-dependent manner. By contrast, no cytotoxic effects were seen within the concentrations used.

Discussion: GW282974 appears to interfere with the inflammatory and the destructive pathways in RASFs and might therefore be used as novel therapeutic strategy for the treatment of RA.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • LCH and PK contributed equally to the study.

  • Funding: This study was partially funded by GlaxoSmithKline.

  • Competing interests: SHB and BSI are employees of the partial sponsor.